CPNG insider files Form 144 for 21,428 Class A shares sale via JP Morgan
Rhea-AI Filing Summary
Form 144 for Coupang, Inc. (CPNG): The filer gave notice of a proposed sale of 21,428 shares of Class A common stock through JP Morgan Securities LLC on 09/11/2025, with an aggregate market value listed as $688,267. The filing states total shares outstanding of 1,665,262,233. The shares were acquired at the IPO on 03/11/2021 (2,143 shares) and 03/18/2021 (19,285 shares) and were paid for in cash. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information about the issuer.
Positive
- Notice filed under Rule 144, providing transparency about a proposed insider/affiliate sale
- Acquisition details disclosed: shares were purchased at IPO on 03/11/2021 and 03/18/2021 and paid in cash
- No securities sold in the past three months for the account to be sold, per the filing
Negative
- None.
Insights
TL;DR: Routine Form 144 notice showing a planned sale of 21,428 Class A shares worth ~$688k; no recent sales reported.
This filing is a standard Rule 144 notice documenting a proposed sale by an insider or affiliate. The size of the position (21,428 shares) is small relative to the stated outstanding shares (1,665,262,233), and the shares were acquired at the IPO in March 2021. Because there are no sales in the prior three months listed, the notice appears to be a discrete liquidity event rather than part of an ongoing disposition program. For investors, this is informational; it does not by itself change fundamentals.
TL;DR: Filing complies with Rule 144 formalities and includes the required attestation about material non-public information.
The form names the broker (JP Morgan Securities LLC), provides acquisition dates and payment method (cash at IPO on 03/11/2021 and 03/18/2021), and notes no prior three-month sales. The representation regarding material adverse information and the explicit signature warning address regulatory disclosure requirements. From a compliance viewpoint, the notice appears complete for the data provided here.